SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Merck: CMV - Cyrus Badshah, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Gilead: RSV - Erik MogalianView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Janssen: Influenza- Thomas Kakuda, PharmDView Slideset
JRJürgen RockstrohMDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Con Standpoint- Jürgen Rockstroh, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Pro Standpoint- Nancy Reau, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin- Su-Young Choi, PharmD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens- Kimberly GarrisonView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme- Omar ElsherifView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilater- Matthew KosloskiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects- Mark Johnson, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_15: Identification of long-acting NRTI candidates through in silico modelling- Marco Siccardi, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration- Steven SancheView Slideset
